SEZ6L2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER
    2.
    发明申请
    SEZ6L2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER 审中-公开
    SEZ6L2 ONCOGENE作为肺癌的治疗目标和预防指标

    公开(公告)号:WO2007116923A2

    公开(公告)日:2007-10-18

    申请号:PCT/JP2007057620

    申请日:2007-03-29

    Abstract: The present invention provides a method for assessing the prognosis of non-small cell lung cancer (NSCLC) using SEZ6L2, as well as methods for evaluating the efficacy of a particular therapy for NSCLC. In addition, the present invention provides kits for prognosing NSCLC. Furthermore, treatment of NSCLC cells with vector-based small interfering RNAs (siRNAs) against the SEZ6L2 gene suppressed its expression and resulted in growth suppression of the NSCLC cells. These results indicate that SEZ6L2 may be useful as a diagnostic marker and as a target for development of new molecular therapies for lung cancer.

    Abstract translation: 本发明提供了一种使用SEZ6L2评估非小细胞肺癌(NSCLC)的预后的方法,以及用于评价特定治疗NSCLC的疗效的方法。 此外,本发明提供了用于预测NSCLC的试剂盒。 此外,针对SEZ6L2基因的基于载体的小干扰RNA(siRNA)治疗NSCLC细胞抑制其表达,并导致NSCLC细胞的生长抑制。 这些结果表明,SEZ6L2可能作为诊断标记和作为肺癌新型分子疗法开发的目标是有用的。

    TTK AS TUMOR MARKER AND THERAPEUTIC TARGET FOR LUNG CANCER
    4.
    发明申请
    TTK AS TUMOR MARKER AND THERAPEUTIC TARGET FOR LUNG CANCER 审中-公开
    TTK作为肿瘤标志物和肺癌的治疗目标

    公开(公告)号:WO2008072777A3

    公开(公告)日:2008-07-31

    申请号:PCT/JP2007074359

    申请日:2007-12-12

    CPC classification number: C12Q1/6886 C12Q2600/118 C12Q2600/136 C12Q2600/158

    Abstract: Disclosed herein is a method for determining kinase activity of TTK for EGFR and methods of screening for modulators of this kinase activity. Also disclosed are methods and pharmaceutical compositions for preventing and/or treating lung cancer that use or include such modulators. Methods for diagnosing lung cancer using the kinase activity of TTK for EGFR protein as an index as well as methods for assessing and prognosing lung cancer are also provided.

    Abstract translation: 本文公开了确定EGFR的TTK的激酶活性的方法和筛选该激酶活性的调节剂的方法。 还公开了用于预防和/或治疗使用或包括这种调节剂的肺癌的方法和药物组合物。 还提供了使用TTK对EGFR蛋白的激酶活性作为指标诊断肺癌的方法以及肺癌的评估和预后的方法。

Patent Agency Ranking